Company Overview and News

 
Defense/Aerospace ETF ITA Continues Flying High

2018-09-06 seekingalpha
The defense and aerospace industry continues to benefit from a rising defense budget and the iShares ETF provides broad exposure to the sector.
LMT HEI.A TDG BOE TXT BA AAXN

158
Tracking Chase Coleman's Tiger Global Portfolio - Q2 2018 Update

2018-09-05 seekingalpha - 6
The largest three positions are Spotify, Amazon.com, and JD.com, and they add up to ~30% of the portfolio.
RDFN BCS NOW HUYA REDU FPI CRM QSR.WI SOGO 83SF FEYE AMZN 83SK TWTR MELI SWCH TEAM PSTG COUP BILI CLDR MSFT JD FB FIT LC MDB DOCU NFLX APO ADBE DESP DBX OKTA QSR 47MC SHOP NETS TDG RUN ZTO MA PVTL AVLR V BKNG IQ ADSK FLT

100
Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2018 Update

2018-09-04 seekingalpha - 1
Stephen Mandel’s 13F portfolio value decreased ~4% from $19.74B to $18.91B. The number of positions decreased from 30 to 28.
STZ.B FB CP SQNXF NOW PYPL GOOG NVDA ADBE ATVI DLTR CP AMZN AVGO CSX MELI TSM IQV EA SQ WYNN TDG TRU TMUSP TMUS STZ EXAS SE BABA BLK BKNG GOOGL MSFT BRCM MHK UNH SBAC

 
TransDigm: Going To Fly Higher

2018-08-21 seekingalpha
The Momentum Growth Quotient for the company is 13.78, which is 37.32% higher than the average for the S&P 100.
TDG

 
Transdigm: Highly Specialized Aerospace Player

2018-08-19 seekingalpha
The company doesn't have many competitors across their wide product portfolio because their offerings are highly specialized and unique.
LMT TDG

 
TDG / Transdigm Group, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TransDigm Group Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 893641100 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
TDG

 
TDG / Transdigm Group, Inc. / Capital World Investors - SC 13G/A (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* TransDigm Group Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 893641100 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
TDG

 
TDG / Transdigm Group, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TransDigm Group Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 893641100 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
TDG

 
TDG / Transdigm Group, Inc. / Capital World Investors - SC 13G/A (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* TransDigm Group Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 893641100 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
TDG

 
TDG / Transdigm Group, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document Table of Contents UNITED STATES
TDG

 
TransDigm Group Incorporated 2018 Q3 - Results - Earnings Call Slides

2018-08-07 seekingalpha
The following slide deck was published by TransDigm Group Incorporated in conjunction with their 2018 Q3 earnings call.
TDG

 
TransDigm (TDG) Q3 Earnings Miss, Up Y/Y on Sales Growth

2018-08-07 zacks
TransDigm Group Incorporated (TDG - Free Report) reported third-quarter fiscal 2018 adjusted earnings of $4.01 per share, which missed the Zacks Consensus Estimate of $4.06 by 1.2%. However, the bottom line improved 19% from $3.37 a year ago.
AJRD LMT TDG TXT

 
TransDigm Group (TDG) Q3 Earnings and Revenues Miss Estimates

2018-08-07 zacks
TransDigm Group (TDG - Free Report) just came out with quarterly earnings of $4.01 per share, missing the Zacks Consensus Estimate of $4.06 per share. This compares to earnings of $3.30 per share a year ago. These figures are adjusted for non-recurring items.
TDG AMT NHI BCRX GTLS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to TDG / Transdigm Group, Inc. on message board site Silicon Investor.

BTDG - B2Digital, Inc. BTDG - B2Digital, Inc. BTDG - B2Digital, Inc.
CUSIP: 893641100